by CM Staff September 20, 2022
The project consortium will develop technologies that are focused on automated and closed-system manufacturing, quality management systems, analytics and regulatory compliance.
NGen Supports Commercial Scale Manufacturing of Cell and Gene Therapies in Canada
HAMILTON &mdsah; Next Generation Manufacturing Canada (NGen), the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing, has announced a $10.5 million contribution to a $34.8 million project led by OmniaBio Inc. (Hamilton) and partners ExCellThera (Montreal), MorphoCell Technologies (Montreal), Aspect Biosystems (Vancouver), and CATTI (Montreal).
Biomanufacturing, which involves complex infrastructure and expertise to manufacture and supply new advanced therapies, does not currently exist on a commercial scale in Canada for cell and gene-based technologies or products. Investment and development in this essential subsector of manufacturing will establish the receptor capacity for the growing number of advanced therapies currently in clinical and pre-clinical development in Canada, which would otherwise need to be manufactured outside the country.
The project consortium, led by OmniaBio, will develop technologies that are focused on automated and closed-system manufacturing, quality management systems, analytics and regulatory compliance.
Project partners ExCellThera, MorphoCell and Aspect Biosystems will deploy resources to advance their respective cell and gene therapy (CGT) programs to proceed to commercial production. Their performance will hopefully demonstrate to the world that Canada is an ideal location for successful CGT ventures to be based.
Spearheaded by the Canadian Advanced Therapies Training Institute (CATTI), the consortium will develop and scale e-learning and on-site cGMP training programs in Quebec and Ontario that will facilitate an unprecedented capacity in Canada for efficient and rapid upskilling of the workforce for CGT biomanufacturing.
“Canada is becoming a world leader in the life sciences sector, and we’re proud to support projects that build on that success. This new $34 million project will not only solidify Canada’s leadership but also help train more Canadians for these good, well-paying jobs,” said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. “Projected to create hundreds of new jobs just in the short term, this new project led by OmniaBio and its consortium partners will make a real difference here at home and around the world.”
“Canada is recognized around the world as a leader in the field of life sciences,” said Jayson Myers, CEO, NGen. “This investment in critical biomanufacturing infrastructure ensures that we will be able to leverage our strengths in research and technology, build a work-ready talent pipeline, and provide the right conditions for our domestic CGT ventures to scale-up in Canada.”
“It will benefit all Canadians to have a thriving cell and gene therapy industry that includes a skilled biomanufacturing workforce, and NGen’s support is key to this project’s success,” explains Mitchel Sivilotti, President and CEO of OmniaBio Inc. “As OmniaBio builds world-leading platform technologies to benefit companies in Canada and around the world, we will see that success translate into more jobs and a strong Life Sciences ecosystem in Canada.”
Canadian Manufacturing is the top source for daily industry-focused news across Canada. We cover the world of manufacturing across all its sectors, sharing stories that impact your business, providing news, in-depth analysis and expert commentary.
Jio marked its entry into the smartphone market earlier this year with the JioPhone Next. Now, the company reportedly has another device in the pipeline